AUTOIMMUNE HEMOLYTIC ANEMIA
Clinical trials for AUTOIMMUNE HEMOLYTIC ANEMIA explained in plain language.
Never miss a new study
Get alerted when new AUTOIMMUNE HEMOLYTIC ANEMIA trials appear
Sign up with your email to follow new studies for AUTOIMMUNE HEMOLYTIC ANEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental 'Triple-Target' drug tested for stubborn autoimmune illnesses
Disease control Recruiting nowThis early study is testing the safety of a new drug called CC312 in adults with severe autoimmune diseases that have not improved with standard treatments. The drug works by engaging the body's own immune T cells to attack harmful B cells, using a mechanism similar to some advan…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
One-Shot cell therapy tested for stubborn autoimmune blood disorders
Disease control Recruiting nowThis early-phase study is testing a new 'universal' CAR-T cell therapy called RD06-05 in adults with severe autoimmune blood diseases that haven't responded well to standard treatments. The main goal is to check the safety of two different doses and see how well the therapy works…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug trial targets stubborn autoimmune blood diseases
Disease control Recruiting nowThis early-stage study is testing an experimental drug called CM336 in adults whose autoimmune blood disorders have not responded to other treatments. The main goals are to see if the drug is safe and if it can help improve patients' blood cell counts. Researchers will monitor fo…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE1, PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Can a 12-Week blood thinner regimen shield patients from Life-Threatening clots?
Prevention Recruiting nowThis study is testing whether taking preventive blood thinners for 12 weeks can stop dangerous blood clots from forming in people with autoimmune hemolytic anemia (AIHA), a rare condition where the immune system attacks red blood cells. People with AIHA have a much higher risk of…
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Prevention
Last updated Apr 01, 2026 22:56 UTC
-
France launches major study to track rare blood disorder patients
Knowledge-focused Recruiting nowThis study is creating a national registry to track 1500 adult patients in France who have immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The goal is to understand how these rare blood disorders progress in real life and see how well current treatments work …
Matched conditions: AUTOIMMUNE HEMOLYTIC ANEMIA
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC